Hims & Hers Health Forecast to 2030
Illustrative modelExplore assumptions. Compare outcomes.
Price baseline: Model recalculated: Editorial review:
Three scenarios, one starting point
Illustrative price paths based on historical returns.
The shaded area spans the lower and upper scenarios; it is not a confidence interval.
The Lower scenario still assumes gains versus the baseline price. Losses outside this range are possible.
What changes the outcome?
Model inputs used in the Hims & Hers Health calculation, then separate market context that is not fed into the model.
Model inputs
Historical price returns (model input)
Weighted windows (3Y, 5Y, 10Y) of historical close-to-close price returns set the starting annual rate for Hims & Hers Health. Dividends are not included.
Drawdown adjustment (model input)
Historical max drawdown near 87.3% scales the risk adjustment applied to the weighted rate before Lower/Base/Upper multipliers.
Category cap & decay (model input)
Annual rates are capped near 25% for this asset class and then decay slightly each projected year (mean reversion), so path CAGR can differ from the starting rate.
Context only
Market context (not a model input)
Earnings, margins, valuation, and sector news can move real prices—but they are not inputs to this price-return model.
Year-by-year forecast
Modeled prices by year. Percentages in parentheses are year-over-year price changes from the prior year (or from the baseline price for the first year)—not the scenario’s starting annualized rate. Price returns only; dividends are not included.
| Year | Lower scenario | Base scenario | Upper scenario |
|---|---|---|---|
| 2027 | $36.53 (+8.5%) | $38.43 (+14.1%) | $39.85 (+18.3%) |
| 2028 | $39.46 (+8.0%) | $43.57 (+13.4%) | $46.78 (+17.4%) |
| 2029 | $42.46 (+7.6%) | $49.09 (+12.7%) | $54.49 (+16.5%) |
| 2030 | $45.51 (+7.2%) | $54.97 (+12.0%) | $62.98 (+15.6%) |
Comparison to benchmark
Benchmark: S&P 500 (SPY) · SPDR S&P 500 ETF Trust forecast
Equivalent comparison unavailable — baseline dates differ (Hims & Hers Health: 2026-07-16, SPDR S&P 500 ETF Trust: 2026-10-30; horizon end 2030-12-31 / 2030-12-31).
Drawdown history windows differ: Hims & Hers Health (2019-09-13 → 2026-07-16) vs SPDR S&P 500 ETF Trust (2011-06-27 → 2026-10-30).
Max drawdown is peak-to-trough depth in the listed history window—not a volatility measure.
Equivalent base-scenario path CAGR vs S&P 500 (SPY) is not shown; historical max drawdown is deeper than the benchmark; drawdown windows are not identical.
Weighted historical price returns
The base rate is a weighted average of available 3Y, 5Y, and 10Y close-to-close price CAGRs, then capped by asset class and scaled by a drawdown-based risk factor. Earnings, revenue, profits, and valuation are not inputs.
Lower / Base / Upper scenarios
Three candidate annual rates use 0.6× / 1.0× / 1.3× of the risk-adjusted base, then are sorted so Lower ≤ Base ≤ Upper. When the base rate is negative, 1.3× becomes the Lower path and 0.6× the Upper path. Chart lines connect annual model points with straight segments. Each projected year also applies mean-reversion decay, so path CAGR can differ from the starting annual rate.
Exact-year duration
Path CAGR uses exact years = (end date − start date) / 365.25 days (Δt / 365.25), matching CalculatorInvest return tools. Horizon end date is 2030-12-31. Formula: (final / baseline)^(1 / years) − 1.
Market cap (when shown)
Market cap is a separate provider snapshot (CoinGecko for crypto; Yahoo quote marketCap for stocks/ETFs when available). It is not an input to the price-path model. ETF figures are quoted market value / approximate AUM. Forex, indexes, and commodities omit market cap.
Educational limitation
Outputs are illustrative price-only scenarios for learning and comparison—not confidence intervals, probability bands, or advice. The chart band is only the span between Lower and Upper paths. Max drawdown is historical peak-to-trough depth, not volatility.
Methodology · Data sources · Full forecast methodology · Limitations & disclaimer
Scenario paths extrapolate historical price returns with category growth caps and a drawdown-based risk adjustment. They do not model dividends, taxes, fees, liquidity, earnings, or valuation. The shaded chart band is the span between Lower and Upper scenarios—not a statistical confidence interval. Max drawdown is historical peak-to-trough depth, not volatility.
What is the Hims & Hers Health forecast for 2030?
This page shows Lower, Base, and Upper scenario price paths for Hims & Hers Health through 2030. Paths extrapolate risk-adjusted weighted historical price returns (price only). The chart band spans Lower and Upper scenarios—not a confidence interval.
Is this forecast guaranteed?
No. Forecasts are scenario-based educational estimates. Actual prices and returns can differ materially from any modeled path.
What inputs does the model use?
Model inputs are historical close prices only: weighted 3Y/5Y/10Y price-return windows where available, a category growth cap, a drawdown-based risk adjustment, and mean-reversion decay. Earnings, revenue, profits, and valuation are not model inputs.
How do Lower and Upper scenario multipliers work?
The model forms three candidate rates at 0.6×, 1.0×, and 1.3× of the risk-adjusted base rate, then sorts them so Lower ≤ Base ≤ Upper. When the base rate is negative, 1.3× becomes the Lower path and 0.6× the Upper path.
How is base-scenario CAGR calculated?
Base-scenario CAGR · price only uses (final price / baseline price)^(1 / exact years) − 1, where exact years = (end date − start date) / 365.25 days, from the baseline close date to 2030-12-31. It is not the model’s starting annual rate when decay changes rates over time.
How often is this forecast updated?
Figures refresh when underlying price history is updated—currently shown as November 2026. Revisit the page for the latest scenario inputs.
Can I compare Hims & Hers Health with another asset?
Yes. Use the comparison chips on this page, the compare tool, or open related forecast cards to review scenario estimates side by side.
Is this financial advice?
No. This is educational scenario context only—not investment advice, a recommendation to buy or sell, or a guarantee of future performance.
